Therapeutic Asset Ratings

1,045 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Gemtuzumab Ozogamicin acute myelomonocytic leukemia M4	National Cancer Institute (NCI)	P2	BB (64)
Gemtuzumab Ozogamicin acute erythroid leukemia	National Cancer Institute (NCI)	P2	BB (64)
Polatuzumab Vedotin indolent B-cell non-Hodgkin lymphoma	University of Washington	P2	BB (64)
rc48-adc DLBCL	Seoul National University Hospital	P2	BB (64)
Trastuzumab Emtansine HER-2 Positive Breast Cancer	Dana-Farber Cancer Institute	P2/3	BB (64)
Mylotarg acute myeloid leukemia	Shaare Zedek Medical Center	P4	B (63)
Brentuximab Vedotin Brentuximab Vedotin	Assistance Publique - Hôpitaux de Paris	P3	B (63)
Brentuximab Vedotin diffuse large B-cell lymphoma	University Medical Center Groningen	P3	B (63)
Brentuximab Vedotin peripheral T-cell lymphoma, not otherwise specified	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	P3	B (63)
Datopotamab Deruxtecan non-small cell lung carcinoma	Memorial Sloan Kettering Cancer Center	P3	B (63)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide breast cancer	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (63)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide non-small cell lung carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (63)
Sacituzumab Tirumotecan non-small cell lung carcinoma	Hunan Province Tumor Hospital	P3	B (63)
Trastuzumab Deruxtecan HER2 positive breast carcinoma	SWOG Cancer Research Network	P3	B (63)
Trastuzumab Emtansine inflammatory breast carcinoma	Hoffmann-La Roche	P3	B (63)
Trastuzumab Emtansine invasive breast carcinoma	Massachusetts General Hospital	P3	B (63)
Trastuzumab Emtansine Her2-receptor negative breast cancer	University of Chicago	P2	B (63)
Trastuzumab Emtansine malignant pancreatic neoplasm	OHSU Knight Cancer Institute	P2	B (63)
T-Dxd HER2 positive breast carcinoma	Peking University Cancer Hospital & Institute	P2/3	B (63)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) urinary bladder carcinoma	Merck Sharp & Dohme LLC	P3	B (62)
Immunoglobulin G1 [240-alanine,241-alanine], anti-(human folate receptor ?) (human monoclonal PRO1184 ?1-chain, complex with human monoclonal PRO1184 ?-chain, dimer, 214??,214???,226,226?,232,232?,235,235?-octakis(thioether) with N6-[39-[bis(1-deoxy-D-glucitol-1-yl)amino]-1-oxo-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxanonatriacont-1-yl]-N2-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-lysyl-L-valyl-N5-(aminocarbonyl)-N-[4-[[[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]oxy]methyl]phenyl]-L-ornithinamide ovarian cancer	Genmab	P3	B (62)
Loncastuximab Tesirine Refractory Diffuse Large B-Cell Lymphoma	University of Utah	P3	B (62)
Polatuzumab Vedotin large B-cell lymphoma	Ruijin Hospital	P3	B (62)
rc48-adc Colonic Neoplasms	First Affiliated Hospital of Guangxi Medical University	P3	B (62)
rc48-adc Esophageal Adenocarcinoma	BeOne Medicines	P3	B (62)

Showing 76 to 100 of 1,045 assets

PreviousPage 4 of 42Next